Any builder will tell you that strength lies in the crosspieces, where framework or walls intersect.
This issue of LEAP celebrates intersections: between clinicians and biological scientists, between both of those groups and information scientists, between specialists of different disciplines.
Hopkins researchers found that dermatomyositis patients with anti-Mi2 antibodies have more severe muscle disease but demonstrate improvement in muscle strength after treatment.
In this study, nearly half of patients that developed inflammatory arthritis after being treated with cancer immunotherapy still had active arthritis 6 months after their last immunotherapy treatment.
In this study, Hopkins investigators sought to determine the time to Lupus Low Disease Activity State attainment in a group of lupus patients and identify useful predictors of achieving this low disease state.
This study from the Johns Hopkins Scleroderma Center found that scleroderma patients with multiple autoimmune responses may be protected from the development of cancer.
Alice in Wonderland may come to mind as you read this issue of LEAP, because we are moving from the large to the small, and back again: A rheumatic disease is big, and its effect can be devastating. However, a disease such as rheumatoid arthritis, scleroderma, or Sjögren’s is, in fact, multiple diseases, each slightly different.
